CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment and to substantially improve treatment options for patients with cancer.
By making tumors accessible and susceptible again for the patient‘s own immune system CatalYm has developed its approach to overcome major limitations of existing immunotherapies and to improve cancer patient survival and quality of life.
CatalYm is led by an experienced management team of serial biotechnology entrepreneurs and backed by international venture capital investors.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.